* Somatogen Inc., of Boulder, Colo., has received $1 million from EliLilly and Company, of Indianapolis, after reaching the first milestonein the companies' collaboration over development of Somatogen'srecombinant hemoglobin product, rHb1.1, for use as a blood substitute.Under terms of the alliance, announced June 27, Lilly made an initial$20 million equity investment in Somatogen and will pay an additional$15 million based on milestones.* Advanced Tissue Sciences Inc., of La Jolla, Calif., filed a supplementto its investigational device exemption requesting FDA approval of apivotal clinical trial of Dermagraft-Transitional Covering.

(c) 1997 American Health Consultants. All rights reserved.